New research shows that ketamine reduces self-dislike, loosening the rigid prejudice toward oneself that can constitute depression.
Experiential avoidance is one transdiagnostic process that may be implicated in the therapeutic benefits of psychedelics.
While ketamine produces a whole symphony of effects in the brain, surprisingly, a localized neural oscillation in a lesser-known area of the brain is enough to cause feelings of dissociation.
Both have long-lasting positive effects on mood, social skills and neuroplasticity. Combining them may potentiate and prolong mutual therapeutic effects.
Research suggests that BDNF can help rewire and overwrite stubborn neural pathways by creating new connections that facilitate more flexible and adaptive thoughts and behaviours. Psychedelics appear to tap into this mechanism.
THC binding to 5-HT2A may activate signaling pathways that cause negative effects on cognition and memory.
In the wake of Covid-19, psychedelic-assisted therapy is gaining attention.
The first trial will determine the sublingual dose equivalent to 25 mg psilocybin administered orally.
The new REBUS model helps explain the subjective and neurochemical effects of psychedelics on the brain.
Psychedelic Science Review Editor Barb Bauer conducts a review of some landmark studies.